Taken together, our study shows the tumor-suppressive function of EZH2 under nutrient-deficient conditions, which partially explains why the clinical expression of EZH2 does not affect the prognosis of CRC patients and reveals a possible mechanism of the resistance of cancer cells to EZH2 inhibitors from the perspective of metabolism. Here, EZH2 is linked to cancer.